Value
6.0/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 0.1 |
| P/S | 9.2 |
| EV/EBITDA | 0.0 |
| Fwd P/E | 6.5 |
| PEG | 10.0 |
| Analyst target | 7.5 |
- ▸Forward P/E: 19.6x
- ▸PEG: 0.05
OMCL · Why this verdict
Why Omnicell (OMCL) is rated HOLD
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictHOLD
Overall score5.6/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Omnicell converts free cash flow at 551% of net income and holds a Piotroski F-Score of 8/9, reflecting high-quality recurring revenue from its pharmacy automation and services business where customers pay upfront or in advance, creating cash flows that substantially exceed reported accounting earnings. Quality breakdown | Free cash flow conversion remains above 300% of net income over the next 4 reported quarters, confirming the structural quality of the revenue model. | →Stable |
| CounterA very high free cash flow to net income ratio in a healthcare IT company can reflect large stock-based compensation charges that reduce GAAP earnings without reducing cash — a compensation cost that dilutes shareholder value even if it does not consume cash. | ||
With a PEG ratio of 0.05 and analysts projecting 53% upside to consensus targets at approximately $53, Omnicell appears priced at a significant discount to its growth trajectory, suggesting the market has not yet fully valued the healthcare automation opportunity. Valuation breakdown | Stock price rises above $50 within 12 months as analyst targets are progressively achieved through earnings delivery. | →Stable |
| CounterA PEG of 0.05 is an extreme reading that likely reflects earnings at a trough with high projected recovery rather than genuine undervaluation, and the current price of $40 near the 52-week mid-range suggests the market is appropriately skeptical of the recovery timeline. | ||
Omnicell beat earnings estimates in 3 of the last 4 quarters with an average positive surprise of 38.5%, including beats of 66% and 67% in two recent quarters, indicating that the healthcare automation business is generating profits well above analyst models. Earnings | Earnings beat streak extends to at least 3 of the next 4 quarters as pharmacy automation adoption continues in hospital systems. | →Stable |
| CounterThe one miss was -19.4% and the large positive surprises may reflect lumpy revenue recognition from multi-year automation contracts rather than sustainable sequential improvement, creating uncertainty about the reliability of the beat pattern. | ||
Momentum has fallen below the minimum required threshold of 4.5 at a score of 4.1, and the current price of $40 is significantly above the options market's max pain level of $35, creating dual technical and options-market headwinds that suggest the near-term path of least resistance may be sideways to lower. Risk breakdown | Momentum score recovers above 5.0 within 3 months as price consolidates above the $35 max pain level and volume patterns normalize. | →Stable |
| CounterMomentum weakness and options market max pain misalignment are short-term technical factors that tend to self-correct, especially when the underlying business is generating strong earnings beats and analysts maintain high price targets. | ||
Omnicell converts free cash flow at 551% of net income and holds a Piotroski F-Score of 8/9, reflecting high-quality recurring revenue from its pharmacy automation and services business where customers pay upfront or in advance, creating cash flows that substantially exceed reported accounting earnings.
→StableQuality breakdown
- Expectation
- Free cash flow conversion remains above 300% of net income over the next 4 reported quarters, confirming the structural quality of the revenue model.
CounterA very high free cash flow to net income ratio in a healthcare IT company can reflect large stock-based compensation charges that reduce GAAP earnings without reducing cash — a compensation cost that dilutes shareholder value even if it does not consume cash.
With a PEG ratio of 0.05 and analysts projecting 53% upside to consensus targets at approximately $53, Omnicell appears priced at a significant discount to its growth trajectory, suggesting the market has not yet fully valued the healthcare automation opportunity.
→StableValuation breakdown
- Expectation
- Stock price rises above $50 within 12 months as analyst targets are progressively achieved through earnings delivery.
CounterA PEG of 0.05 is an extreme reading that likely reflects earnings at a trough with high projected recovery rather than genuine undervaluation, and the current price of $40 near the 52-week mid-range suggests the market is appropriately skeptical of the recovery timeline.
Omnicell beat earnings estimates in 3 of the last 4 quarters with an average positive surprise of 38.5%, including beats of 66% and 67% in two recent quarters, indicating that the healthcare automation business is generating profits well above analyst models.
→StableEarnings
- Expectation
- Earnings beat streak extends to at least 3 of the next 4 quarters as pharmacy automation adoption continues in hospital systems.
CounterThe one miss was -19.4% and the large positive surprises may reflect lumpy revenue recognition from multi-year automation contracts rather than sustainable sequential improvement, creating uncertainty about the reliability of the beat pattern.
Momentum has fallen below the minimum required threshold of 4.5 at a score of 4.1, and the current price of $40 is significantly above the options market's max pain level of $35, creating dual technical and options-market headwinds that suggest the near-term path of least resistance may be sideways to lower.
→StableRisk breakdown
- Expectation
- Momentum score recovers above 5.0 within 3 months as price consolidates above the $35 max pain level and volume patterns normalize.
CounterMomentum weakness and options market max pain misalignment are short-term technical factors that tend to self-correct, especially when the underlying business is generating strong earnings beats and analysts maintain high price targets.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Omnicell offers a compelling combination of 33% analyst upside, a PEG of 0.05, and free cash flow conversion of 551% relative to net income alongside a Piotroski F-Score of 8/9, but momentum has slipped below the minimum threshold and the stock trades well above the options market's max pain level of $35.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
4.5/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.5 |
| ROA | 0.8 |
| Gross margin | 4.8 |
| Op margin | 2.2 |
| Net margin | 0.8 |
| Current ratio | 5.5 |
| FCF quality | 10.0 |
| Moat | 7.1 |
| Piotroski F | 8.9 |
- ▸Excellent cash conversion: 551% FCF/NI
- ▸Strong Piotroski F-Score: 8/9
Growth
6.2/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 6.2 |
Momentum
6.8/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.1 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 0.7 |
- ▸Overbought (RSI 78)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
7.6/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 6.0 |
| Analyst rating | 7.7 |
| Price target | 9.3 |
- ▸Light analyst coverage (7.0) — signal dampened
- ▸Analyst upside: 42%
Insider
5.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.1 |
- ▸Insider selling (low materiality) — $350,730 (0.018% of mkt cap)
Peer rank
3.5/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 3.8 |
| quality rank | 5.2 |
| growth rank | 5.0 |
Technical
2.9/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.1 |
| support resistance | 1.9 |
| 52w position | 5.6 |
Risk (lower is worse)
5.8/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 5.8 |
| days to cover | 4.9 |
| volatility | 2.3 |
| put call | 10.0 |
| implied vol | 1.1 |
| beta | 7.2 |
| debt equity | 9.4 |
- ▸High IV: 73%
Catalyst
6.3/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| news activity | 5.0 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
Mixed signals. Hold existing position.
Engine technical detail
verdict_path:
L4:PATH_F_HOLD_DEFAULTPassed (7)
- MOMENTUM:6.8>=5.5
- ASYMMETRY:1.6>=1.5
- INSIDER:OK
- 8K:CLEAN
- EARNINGS_PROXIMITY:27d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (0)
none
Reward-to-Risk
1.59
Upside
+23.9%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeCatalyst-Driven — Earnings in 27d with 3/4 beat streak
SuitabilityAggressive — MCap $2.0B<$5B
Investment implication
The default F-path HOLD fired without any positive-conviction gate triggering — no momentum acceleration, no quality+value crossover, no setup recognition. Highest-clear gate: MOMENTUM:6.8>=5.5. Top dim: Sentiment at 7.6; weakest: Technical at 2.9. The engine's read is one of pattern absence — no directional conviction in either direction at current asymmetry.
The strongest dimensions are Sentiment at 7.6, Momentum at 6.8, and Catalyst at 6.3; the weakest are Technical at 2.9, Peer rank at 3.5, and Quality at 4.5. The V9 engine cleared all gates, producing an asymmetric reward-to-risk of 1.59 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Exceptional Fcf Piotroski Quality
Trip ifFree cash flow conversion falls below 200% of net income for 2 consecutive quarters, indicating the structural quality advantage is deteriorating.
- P2Analyst Upside Peg Value
Trip ifAnalyst consensus price target falls below $45, reducing projected upside to less than 13% from current price levels.
- P3Earnings Beat Streak
Trip ifEPS surprise falls below -15% in at least 2 of the next 3 quarters, indicating the beat pattern has reversed.
- P4Momentum Below Threshold Max Pain
Trip ifStock price drops below $35 (the current options max pain level) and stays below it for more than 20 trading days, confirming options-market headwinds are exerting sustained pressure.